Answers are grounded in this paper and cite their sources.
Systematic evolution of ligands by exponential enrichment (SELEX)-based aptamer discovery can be constrained by target availability, selection biases, and optimization requirements. We introduce Xelari, a modular pipeline for de novo DNA and RNA aptamer design from protein structures without target-specific SELEX data or retraining. Xelari combines algorithmic modules with surrogate models trained on physical or structural references. InNA reproduced nucleotide-amino-acid interaction energies with RMSE of 0.19 kcal/mol across 483,735 reference pairs. AliNA achieved a mean F1 of 0.757 on 339 PDB-derived RNA evaluation sequences. Edgar correlated with experimental folding energies but did not reproduce their absolute scale, supporting its use as a ranking heuristic. Under the reported calibration, ValentiNA showed MAE of 0.931 kcal/mol and Spearman ρ of 0.795 across 32 retrospective records associated with 27 structural templates; this analysis does not establish family-independent validation. Prospectively, three DNA aptamers designed against Treponema pallidum protein structures showed cell-associated binding in a treponeme assay (apparent KD, 0.91–2.57 μM). A fourth DNA aptamer served as a capture reagent in a serum-based hybrid aptamer-antibody assay for Tau441. These applications support feasibility without establishing intended-target engagement in the cellular assay or a general success rate, positioning structure-based design as a complement to experimental selection.
No takes yet. Share an insight, caveat, or question.
Dolgusheva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: